Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Upcoming patient data

<< Previous

Bullboard Posts

Next >>

Comment by greaterfoolFredon Feb 19, 2022 6:42pm

215 Views

Post# 34445503

RE:RE:RE:RE:Upcoming patient data

I have a question, but am too lazy to find out for myself, and I am sure that most of you already know the answer. Who are the patients being treated in the "N-803 + BCG for CIS disease" trial. Have these people already failed BCG treatment (like in our 1433 trial?) Or is this their first treament using BCG? Thanks, and good luck all.

<< Previous

Bullboard Posts

Next >>

Shopify stock hits year-high on Q3 results